Lake Success

Running trials

• Active, not recruiting

  Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

  NCT04305496· Phase 3· Source

• Active, not recruiting

  To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

  NCT03330847· Phase 2· Source

• Active, not recruiting

  A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

  NCT02972840· Phase 3· Source

• Active, not recruiting

  A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

  NCT02717624· Phase 1· Source

• Active, not recruiting

  A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

  NCT02717611· Phase 2· Source

• Active, not recruiting

  Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

  NCT02477696· Phase 3· Source

• Active, not recruiting

  Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

  NCT02475681· Phase 3· Source

• Active, not recruiting

  Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

  NCT02180711· Phase 1/2· Source

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

  NCT05592483· Source